NCT00620282 trial results

Inclusion Criteria: * Type 2 diabetes * Diet and lifestyle changes or metformin monotherapy for at least three months * HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive) * Body Mass Index (BMI) less than or equal to 40 kg/m\^2 Exclusion Criteria: * Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator) * Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial * Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening * Current smoker or history of smoking within 6 months prior to screening * Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease) * Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator * Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator * Known autonomic neuropathy, as judged by the Investigator * Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening * Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg